After dazzling at conference, Janssen leaders pledge to go further

Janssen has been on a good run of form recently.

Its potential blockbuster depression therapy, esketamine, has been posting good trial results and its ViiV Healthcare-partnered HIV combination Juluca (dolutegravir 50g/rilpivirine 25g) received European approval in late May, all after closing on a deal to acquire Benevir Biopharma.

And then the company dazzled at ASCO, scoring two presentations in the conference’s 'best of' selection and revealing its first treatment for urothelic cancer, while in the hematology space, combining Janssen's Imbruvica (ibrutinib) with Rituxan/MabThera (rituximab) saw risk of death or symptom progression from Waldenstrom’s Macroglobulinemia fall by 80%.